Ignite Creation Date:
2024-05-06 @ 3:59 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04832880
Status:
UNKNOWN
Last Update Posted:
2021-04-06
First Post:
2020-10-12
Brief Title:
Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 the AMMURAVID Trial
Sponsor:
ASST Fatebenefratelli Sacco
Organization:
ASST Fatebenefratelli Sacco
Study Overview
Official Title:
Factorial Multicentric Randomized Clinical Trial of Remdesivir and Immunotherapy in Combination With Dexamethasone for Moderate COVID-19 the AMMURAVID Trial
Status:
UNKNOWN
Status Verified Date:
2021-04
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AMMURAVID
Brief Summary:
Background
In the current worldwide medical emergency a rapid identification of effective therapeutic strategy is crucial So far therapy with dexamethasone remdesivir and baricitinib have been associated with evidence of impact on the clinical impact on COVID-19 but the effect of baricitinib and remdesivir in combination with dexamethasone
The AAMMURAVID trial is endorced and supported by the Italian Regulatory agency AIFA-Agenzia Italiana del Farmaco
In the current worldwide medical emergency a rapid identification of effective therapeutic strategy is crucial So far therapy with dexamethasone remdesivir and baricitinib have been associated with evidence of impact on the clinical impact on COVID-19 but the effect of baricitinib and remdesivir in combination with dexamethasone
The AAMMURAVID trial is endorced and supported by the Italian Regulatory agency AIFA-Agenzia Italiana del Farmaco
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-001854-23 | EUDRACT_NUMBER | None | None |